Circassia Pharmaceuticals Plc (CIR) - Medical Equipment - Deals and Alliances Profile
October 2018
53
About the Report
About the Report
Summary
Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company's marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.
Circassia Pharmaceuticals Plc (CIR)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Circassia Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Medical Equipment, Deal Details 10
Venture Financing 10
Prosonix Raises Additional USD 9 Million In Series B Financing Round 10
Partnerships 12
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 12
Aerocrine Enters Into Licensing Agreement With Medisoft 13
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 14
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 15
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 16
Equity Offering 17
Aerocrine Raises USD60 Million in Rights Offering of Shares 17
Aerocrine Completes Private Placement Of Shares For USD 15 Million 19
Aerocrine Completes Rights Offering Of Common Stock For USD 36 Million 20
Acquisition 21
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 21
Circassia Pharmaceuticals Acquires Aerocrine 22
Circassia Pharma Acquires Prosonix for USD157.6 Million 24
Circassia Pharmaceuticals Plc-Key Competitors 26
Circassia Pharmaceuticals Plc-Key Employees 27
Circassia Pharmaceuticals Plc-Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Sep 27, 2018: Circassia-Interim results for the six months ended 30 June 2018 29
Sep 27, 2018: Circassia Pharmaceuticals interim results for the six months ended 30 june 2018 33
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 47
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 48
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 49
Corporate Communications 50
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 50
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 51
Government and Public Interest 52
Nov 29, 2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Figure
List of Figures
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8
List of Table
List of Tables
Circassia Pharmaceuticals Plc, Medical Equipment, Key Facts, 2017 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Deals By Market, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Prosonix Raises Additional USD 9 Million In Series B Financing Round 10
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 12
Aerocrine Enters Into Licensing Agreement With Medisoft 13
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 14
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 15
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 16
Aerocrine Raises USD60 Million in Rights Offering of Shares 17
Aerocrine Completes Private Placement Of Shares For USD 15 Million 19
Aerocrine Completes Rights Offering Of Common Stock For USD 36 Million 20
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 21
Circassia Pharmaceuticals Acquires Aerocrine 22
Circassia Pharma Acquires Prosonix for USD157.6 Million 24
Circassia Pharmaceuticals Plc, Key Competitors 26
Circassia Pharmaceuticals Plc, Key Employees 27
Circassia Pharmaceuticals Plc, Subsidiaries 28
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.